Skip to main content
Deciphera
Deciphera
  • Patients & Caregivers
  • Healthcare Professionals
  • Clinical Studies
  • Presentations & Publications
  • News
twitter linkedin
  • Discovery Platform
  • Pipeline
    • Ripretinib
    • Vimseltinib
    • Tirabrutinib
    • Sapablursen
    • ONO-4578
    • ONO-2808
    • ONO-2020
    • DCC-3009
    • Inlexisertib
    • DCC-2812
    • ONO-4685
    • Expanded Access
  • Our Medicine
  • About
    • Management
  • Join Us
    • Open Positions
  • Discovery Platform
  • Pipeline
    • Ripretinib
    • Vimseltinib
    • Tirabrutinib
    • Sapablursen
    • ONO-4578
    • ONO-2808
    • ONO-2020
    • DCC-3009
    • Inlexisertib
    • DCC-2812
    • ONO-4685
    • Expanded Access
  • Our Medicine
  • About
    • Management
  • Join Us
    • Open Positions
  • Patients & Caregivers
  • Healthcare Professionals
  • Clinical Studies
  • Presentations & Publications
  • News
twitter linkedin

News

News

Archive
June 2, 2022

Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences

Archive
May 4, 2022

Deciphera Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results

Archive
May 2, 2022

Deciphera Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 4, 2022

Archive
April 29, 2022

Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Archive
April 27, 2022

Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants

Archive
April 26, 2022

Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Archive
April 12, 2022

Deciphera Pharmaceuticals Presents Preclinical Data from DCC-3116 Program at the AACR Annual Meeting

Archive
March 9, 2022

Deciphera Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference

Archive
February 8, 2022

Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results

Archive
February 2, 2022

Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences

Pagination

  • First page ‹‹ First
  • Previous page ‹ Prev
  • …
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Current page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • …
  • Next page Next ›
  • Last page Last ››
Displaying 71 - 80 of 271
Deciphera
twitter linkedin
contact us
  • Discovery Platform
  • Pipeline
    • Ripretinib
    • Vimseltinib
    • Tirabrutinib
    • Sapablursen
    • ONO-4578
    • ONO-2808
    • ONO-2020
    • DCC-3009
    • Inlexisertib
    • DCC-2812
    • ONO-4685
    • Expanded Access
  • Our Medicine
  • About
    • Management
  • Join Us
    • Open Positions
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Recruiting Privacy Policy
  • Web Accessibility Statement
  • Compliance Hotline
  • Consent Manager

© 2025 Deciphera Pharmaceuticals, LLC. The following are registered trademarks of Deciphera Pharmaceuticals, LLC: QINLOCK, the QINLOCK logo, DECIPHERA, and the Deciphera logo. The following are trademarks of Deciphera Pharmaceuticals, LLC: ROMVIMZA and the ROMVIMZA logo.

Back to top